Weight Loss and GLP-1 Patches: What the Law, the FTC and the Labels Say (2026)

As of September 2026, the FDA has approved zero transdermal (skin patch) products for weight management, and zero GLP-1 medicines come as a patch. We checked the openFDA drug label database on September 29, 2026: of the 315 labels with the route "TRANSDERMAL", none is indicated for weight management or obesity, and the 45 labels in the GLP-1 receptor agonist class list a subcutaneous or an oral route, never a transdermal one. Do weight loss patches work? None of the listings we read states in its product description that the patch causes weight loss, even where the product name says "weight loss": each is marketed as a wellness or botanical product whose own listing says it is not intended to treat any disease, and the FTC's consumer guidance states that nothing you can wear or apply to your skin will cause you to lose weight. The medicines the FDA has approved for long-term weight management are all prescription-only injections, capsules or tablets.

*What this guide covers:*

• What the law says a weight loss patch is, and is not
• What the FTC has said and done about weight-loss patches
• What the sellers' own listings say
• GLP-1 patches and the "Ozempic patch": what the FDA record shows
• Whether skin can deliver a weight-loss ingredient or a GLP-1 peptide
• Which weight-management medicines are FDA-approved, and in what forms
• A checklist for telling a medicine from a wellness patch
• Safety questions to bring to a physician

What the law says a weight loss patch is, and is not

A medicine approved for weight management goes through FDA review before it is sold, and its label is the record of that review. A dietary supplement does not. The FDA's consumer page puts it in capitals: "The FDA does NOT have the authority to approve dietary supplements for safety and effectiveness, or to approve their labeling, before the supplements are sold to the public." Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), firms "are responsible for evaluating the safety and labeling of their products before marketing," and the FDA "has the authority to take action against any adulterated or misbranded dietary supplement product after it reaches the market." Patches add a wrinkle. The federal definition of a dietary supplement at 21 U.S.C. 321(ff) covers a product "intended to supplement the diet" that contains a vitamin, mineral, "herb or other botanical" or similar ingredient and "is intended for ingestion." A patch is worn, not swallowed. One large patch seller says so on its own site: "PatchAid wellness patches are topical wellness products intended solely for general wellness and lifestyle support. They are not medical devices or dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease or medical condition." Either way, no agency reviewed the product's weight claims before it went on sale.

That disclaimer is required, not volunteered. Under 21 CFR 101.93, a supplement making a "structure/function" claim must carry the sentence: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." The sentence, or the asterisk pointing to it, is the product saying in the regulation's own words that it is not a medicine.

What does the FTC say about weight-loss claims for patches?

The FDA regulates what a product is. The Federal Trade Commission regulates advertising, and it has written about patches by name.

The FTC's Health Products Compliance Guidance sets the standard: "claims about the health benefits or safety of foods, dietary supplements, drugs, and other health-related products require substantiation in the form of competent and reliable scientific evidence." The FTC's consumer page on weight loss ads lists the promises it calls false. One is "Lose weight with this patch or cream. (You can't.)" The page also states: "Nothing you can wear or apply to your skin will cause you to lose weight. Period." The FTC's Gut Check, its reference guide for media on spotting false weight loss claims, is as direct: "Weight loss is an internal metabolic process. Nothing you wear or apply to the skin can cause substantial weight loss. So weight loss claims for patches, creams, lotions, wraps, body belts, earrings, and the like are false."

The agency has acted on that view. A December 2004 press release titled "FTC: Skin Patches Do Not Cause Weight Loss" describes suits against a patch manufacturer and a retailer alleged to have "falsely claimed that the skin patch causes substantial weight loss," and challenges "false claims that the patch or its main ingredient, sea kelp, has been approved by the Food and Drug Administration." The cases continued. On August 20, 2007 the FTC announced that a patch company and its owner were "banned from selling weight-loss patches in the future and will pay $180,000"; the advertising had claimed "that it caused weight loss and that the main ingredient, sea kelp, had been approved by the FDA for weight loss." On September 30, 2008 the marketers of another weight-loss patch "agreed to pay $110,539 to settle Federal Trade Commission charges that they violated two 2004 consent orders." Those are historical cases and say nothing about any product on sale today; what they establish is the rule that a patch advertised as causing weight loss needs competent and reliable scientific evidence behind the claim.

Do weight loss patches work? What the sellers' own listings say

We read the product pages of several patches that rank for this search in September 2026.

PatchAid's Natural Weight Loss Enhancer Patch "combines Vitamin B12, folate, and familiar botanicals in one caffeine-free patch," lists kelp, blue-green algae, bromelain and apple cider vinegar, and says plainly: "This patch won't replace balanced nutrition, movement, or medical care." Its Slim Trim Appetite Support Patch lists lotus leaf, saffron, fucoxanthin, berberine, chromium, green tea and other botanicals, and phrases every benefit as a possibility with an asterisk: "May support normal appetite regulation.*" and "May support normal metabolic function.*"

On Amazon, a listing for Thrivia Berberine Patches for Weight Loss and Metabolic Wellness describes "a thin, stick-on patch format" made with "berberine extract, pomegranate extract, cinnamon extract, and L-glutamine," and states the product has "not been evaluated by the Food and Drug Administration" and "is not intended to diagnose, treat, cure, or prevent any disease." Amazon appends its own line to such listings: "Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition."

To be fair to the sellers: none of the listings we read claims FDA approval, and each uses the hedged language the regulations anticipate. The product names carry the pitch. "Weight loss" appears in the name; "May support normal metabolic function" appears in the fine print. A shopper who reads only the name is buying something the label does not promise.

GLP-1 patches and the "Ozempic patch": what the FDA record shows

Some patches borrow the name of a prescription medicine class. As of September 29, 2026, zero GLP-1 medicines with an FDA label come as a skin patch. The openFDA label database counts 44 labels in the GLP-1 receptor agonist class with a subcutaneous route and 1 with an oral route, and none with a transdermal route. Every semaglutide label in openFDA is a subcutaneous injection (4 labels) or an oral tablet (1 label).

There is no "Ozempic patch." Ozempic is Novo Nordisk's brand name for semaglutide, sold as an injection and, on a label shared with Rybelsus, as tablets ("RYBELSUS and OZEMPIC tablets are indicated"). The injection label on DailyMed opens: "OZEMPIC (semaglutide) injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog)." Every indication on both Ozempic labels is in adults with type 2 diabetes; weight management is an indication on the Wegovy label, not on an Ozempic label. Baptist Health reports that the products are sometimes called "Ozempatches"; a product sold under a name like that is using the brand, not the drug.

What the GLP-1-named patches contain is on the sellers' own pages. On September 29, 2026 we read two. Kind Patches titles its product "Berberine Patches (GLP-1 Friendly)" and lists berberine, pomegranate and cinnamon extracts, a vitamin B complex, L-glutamine and chromium. The same page has a comparison table that rates the patch's bioavailability "High, due to direct absortion" [sic], with no measurement of how much of any ingredient crosses skin. PatchAid's Berberine Patch page states: "This is a plant-based wellness patch. It does not contain prescription weight-loss or diabetes medications and is not a substitute for any prescription medication." Neither page lists a GLP-1 receptor agonist. Cleveland Clinic reports that after criticism of GLP-1 patch advertising, "some sellers have rebranded them as berberine patches." A patch named for a GLP-1 medicine is a botanical patch; the name is the only part of the medicine it carries.

Can skin deliver a weight-loss ingredient?

Skin patches are real medicine when the molecule fits. The 315 transdermal labels in openFDA on September 29, 2026 show the route works for nicotine, estradiol, testosterone, fentanyl, methylphenidate and scopolamine. The question is whether a weight-management ingredient can cross skin at a useful rate.

A peer-reviewed review in Nature Biotechnology explains the barrier: "The first-generation approach to transdermal delivery is limited primarily by the barrier posed by skin's outermost layer called stratum corneum," and "First-generation delivery candidates must be low-molecular weight, lipophilic and efficacious at low doses." The authors add: "Perhaps the greatest challenge for transdermal delivery is that only a limited number of drugs are amenable to administration by this route."

Botanical extracts are mixtures, not single small molecules. Nothing on the listings we read reports how much of any ingredient crosses skin; the seller has not shown, and is not required to show, that it delivers anything.

For peptide medicines the size problem is severe. A 2000 paper in Experimental Dermatology set out a rule of thumb for skin: "We argue that the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer." PubChem, the chemistry database of the U.S. National Library of Medicine, lists semaglutide with the molecular formula C187H291N45O59 and a molecular weight of 4114, more than eight times that ceiling. Berberine, which both GLP-1-named brand pages list, has a molecular weight of 336.4 in PubChem. Clearing the 500 dalton line on paper says nothing about how much of it a given patch delivers, and it does not make berberine a GLP-1 medicine.

Microneedle patches for peptides are a research topic, not a product: as of September 29, 2026, no microneedle GLP-1 patch has an FDA label. The Nature Biotechnology review reported in 2008 that "Microneedles and thermal ablation are currently progressing through clinical trials for delivery of macromolecules and vaccines, such as insulin, parathyroid hormone and influenza vaccine." A July 2026 paper in AAPS PharmSciTech describes dissolving microneedles loaded with semaglutide and tested for insertion into pig skin outside the body, a laboratory study. A retail patch described with words such as "microneedle" or "nano" is not that research unless it cites a study and an FDA label.

Which weight-management medicines are FDA-approved, and in what forms?

The NIDDK, part of the National Institutes of Health, introduces its list this way: "The table below lists prescription drugs approved by the FDA for chronic weight management." It names six medicines approved for long-term use: orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide and tirzepatide. We read the label the openFDA label API returns for each medicine on September 19, 2026. Every one is a human prescription drug, and not one is a patch.

• Semaglutide (Wegovy) "is indicated in combination with a reduced calorie diet and increased physical activity"; the label openFDA returns describes an injection in pre-filled pens, and the FDA's Drugs@FDA database also lists Wegovy tablets for oral use under application NDA218316, approved December 22, 2025. Neither form is a patch.
• Tirzepatide injection (Zepbound) is indicated "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition"; an injection in pens and vials.
• Liraglutide injection (Saxenda) is indicated "to reduce excess body weight and maintain weight reduction long term" in patients who meet the label's criteria; an injection in a prefilled pen.
• Phentermine-topiramate (Qsymia): an oral extended-release capsule.
• Naltrexone-bupropion (Contrave): an oral extended-release tablet.
• Orlistat (Xenical): an oral capsule "indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet."

The NIDDK table does not yet list a seventh medicine. Drugs@FDA records the original approval of Foundayo (orforglipron) tablets from Eli Lilly under application NDA220934 on April 1, 2026, and its label says Foundayo "is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition." It is an oral tablet with the route ORAL, and it is not a patch either.

One more label comes up in patch marketing. Semaglutide tablets (Rybelsus, and the tablet form of Ozempic) are indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." That is a diabetes indication, not a weight-management approval, and any prescribing decision belongs to a licensed physician. Our explainer on what a GLP-1 medication is covers the class. Our guide to Zepbound and Wegovy compares the approved options, and our guide to oral and sublingual GLP-1 forms covers non-injection products by label.

Compounded semaglutide and tirzepatide are a separate category. Compounded medications are not FDA-approved as final products. The FDA's compounding page states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." A compounded medicine still requires a prescription written for you and a licensed pharmacy; see whether compounded semaglutide is FDA-approved and 503A versus 503B pharmacies.

Telling a medicine from a wellness patch: a checklist

Run these checks on any product that puts "weight loss" or "GLP-1" next to "patch." Each uses a public record.

1. Look for "Rx only." Under 21 U.S.C. 353(b)(4)(A), a prescription drug is misbranded if its label "fails to bear, at a minimum, the symbol 'Rx only'." A product you can add to a cart without a prescription does not carry it.
2. Look for an NDC, and know its limits. Under 21 CFR 207.33 each listed drug "must have a unique NDC to identify its labeler, product, and package size and type." An NDC alone is not approval: the FDA's NDC Directory page says "Assignment of an NDC number does not in any way denote FDA approval of the product."
3. Find the label on DailyMed or openFDA. Prescription labels are submitted to the FDA in the Structured Product Labeling format and published on DailyMed and through the openFDA label API. No label means no FDA-reviewed labeling.
4. Find the asterisk. A benefit sentence ending in an asterisk that leads to "This statement has not been evaluated by the Food and Drug Administration" is a product telling you it is not a medicine.
5. Read the ingredient panel. For a dietary supplement, 21 CFR 101.36 requires that "The names and the quantitative amounts by weight of each (b)(2)-dietary ingredient shall be presented under the heading 'Amount Per Serving.'" A "proprietary blend" with one total weight tells you less, and no panel tells you how much crosses skin.
6. Ask who prescribed it and who dispensed it. A weight-management medicine reaches you through a prescriber licensed in your state and a pharmacy licensed for your state; the FDA notes that "state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies." A patch shipped from a marketplace involves neither.
7. Apply the FTC's test to the ad. If the pitch matches one of the FTC's listed false promises, including "Lose weight with this patch or cream," the agency has already said the claim cannot be true as stated.

Are weight loss patches safe? Questions to bring to a physician

No agency reviews a wellness patch for safety before it is sold; the FDA's authority over supplements applies after a product reaches the market. The listings we read disclose botanical ingredients, some of which, such as green tea extract, can contain caffeine. Whether that matters for you is a question for a physician who knows your medications and conditions.

For patches sold under the GLP-1 name, Baptist Health lists typical ingredients that include green tea extract, bitter orange extract and guarana, and possible side effects that include skin irritation or rash, increased heart rate, jitteriness or anxiety, trouble sleeping and nausea, adding: "Some ingredients act as stimulants and may raise blood pressure or interact with other medications." PatchAid's Berberine Patch page cautions: "Berberine may affect blood sugar and should not be combined with blood sugar medication without medical supervision." Cleveland Clinic quotes endocrinologist Keren Zhou, MD: "You could also develop an allergic reaction from the patch itself, a condition known as contact dermatitis." A reaction to any patch can be reported to the FDA's MedWatch program, which "receives reports from the public and when appropriate, publishes safety alerts for FDA-regulated products."

If a patch appealed because injections or pills felt like too much, say so to a physician. Useful questions:

• Am I a candidate for any FDA-approved weight-management medicine, and which forms would be options for me?
• I have been looking at a botanical patch with these ingredients. Do any interact with medicines I take or affect a condition I have?
• The patch I bought is sold under a GLP-1 name. Is anything in it a problem with a diabetes medicine I take, and how do I report a reaction?

A physician can say no, and a good one will explain why. Medication is prescribed only if a licensed physician determines it is appropriate.

The bottom line

A weight loss patch is a product the law does not review before sale, in a category the FTC has written about by name, with botanical ingredients whose delivery through skin the seller does not have to demonstrate. The FDA has approved zero transdermal products for weight management as of September 2026. Read the fine print, run the checklist, and put the question of medication to a licensed physician.

What the primary sources say

• U.S. Food and Drug Administration, openFDA drug label API (accessed September 29, 2026): labels with route TRANSDERMAL, "total": 315; the same labels searched for obesity, weight management or weight reduction in their indications return "No matches found!"; GLP-1 receptor agonist class by route: "SUBCUTANEOUS" 44, "ORAL" 1; semaglutide by route: "SUBCUTANEOUS" 4, "ORAL" 1
• Novo Nordisk via DailyMed, Ozempic (semaglutide) injection prescribing information (accessed September 29, 2026): "OZEMPIC (semaglutide) injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog)."; "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus"; Rybelsus and Ozempic tablets label: "RYBELSUS and OZEMPIC tablets are indicated"
• Eli Lilly and Company via DailyMed, Foundayo (orforglipron) tablets prescribing information (accessed September 29, 2026): "is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition"
• U.S. Food and Drug Administration, Drugs@FDA via openFDA, NDA220934 and NDA218316 (accessed September 29, 2026): NDA220934, "FOUNDAYO", "TABLET", "ORAL", "Prescription", original approval "20260401"; NDA218316, "WEGOVY", "TABLET", "ORAL", original approval "20251222"
• National Institute of Diabetes and Digestive and Kidney Diseases, Prescription Medications to Treat Overweight and Obesity (accessed September 29, 2026): "The table below lists prescription drugs approved by the FDA for chronic weight management."
• PubChem, U.S. National Library of Medicine, semaglutide (CID 56843331) and berberine (CID 2353) (accessed September 29, 2026): semaglutide "MolecularFormula": "C187H291N45O59", "MolecularWeight": "4114"; berberine "MolecularWeight": "336.4"
• Bos JD, Meinardi MM, The 500 Dalton rule for the skin penetration of chemical compounds and drugs, Experimental Dermatology 2000, via Europe PMC (accessed September 29, 2026): "We argue that the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer."
• Prausnitz MR, Langer R, Transdermal drug delivery, Nature Biotechnology 2008 (accessed September 29, 2026): "First-generation delivery candidates must be low-molecular weight, lipophilic and efficacious at low doses."; "Perhaps the greatest challenge for transdermal delivery is that only a limited number of drugs are amenable to administration by this route."; "Microneedles and thermal ablation are currently progressing through clinical trials for delivery of macromolecules and vaccines, such as insulin, parathyroid hormone and influenza vaccine."
• Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System, AAPS PharmSciTech, July 2026, via Europe PMC (accessed September 29, 2026): "ex-vivo porcine skin insertion"
• U.S. Food and Drug Administration, Dietary Supplements (accessed September 29, 2026): "are responsible for evaluating the safety and labeling of their products before marketing"; "has the authority to take action against any adulterated or misbranded dietary supplement product after it reaches the market"
• U.S. Food and Drug Administration, Questions and Answers on Dietary Supplements (accessed September 29, 2026): the disclaimer must state that the product is not intended to "diagnose, treat, cure, or prevent any disease" "because only a drug can legally make such a claim"
• 21 U.S.C. 321(ff), via Legal Information Institute (accessed September 29, 2026): "intended to supplement the diet"; "herb or other botanical"; "is intended for ingestion"
• 21 CFR 101.93 and 21 CFR 101.36, via Legal Information Institute (accessed September 29, 2026): "This product is not intended to diagnose, treat, cure, or prevent any disease."; "The names and the quantitative amounts by weight of each (b)(2)-dietary ingredient shall be presented under the heading"
• 21 U.S.C. 353(b)(4)(A) and 21 CFR 207.33, via Legal Information Institute (accessed September 29, 2026): "fails to bear, at a minimum, the symbol"; "must have a unique NDC to identify its labeler, product, and package size and type"
• U.S. Food and Drug Administration, National Drug Code Directory (accessed September 29, 2026): "Assignment of an NDC number does not in any way denote FDA approval of the product"
• Federal Trade Commission, Health Products Compliance Guidance (accessed September 29, 2026): "claims about the health benefits or safety of foods, dietary supplements, drugs, and other health-related products require substantiation in the form of competent and reliable scientific evidence"
• Federal Trade Commission, The Truth Behind Weight Loss Ads and Gut Check (accessed September 29, 2026): "Lose weight with this patch or cream. (You can't.)"; "Nothing you can wear or apply to your skin will cause you to lose weight. Period."; "Nothing you wear or apply to the skin can cause substantial weight loss."
• Federal Trade Commission, press releases of December 15, 2004, August 20, 2007 and September 30, 2008 (accessed September 29, 2026): "falsely claimed that the skin patch causes substantial weight loss"; "banned from selling weight-loss patches in the future and will pay $180,000"; "agreed to pay $110,539 to settle Federal Trade Commission charges that they violated two 2004 consent orders"
• U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers (accessed September 29, 2026): "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."; "state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies"
• U.S. Food and Drug Administration, MedWatch (accessed September 29, 2026): "MedWatch receives reports from the public and when appropriate, publishes safety alerts for FDA-regulated products"
• PatchAid, product pages (accessed September 29, 2026): "This is a plant-based wellness patch. It does not contain prescription weight-loss or diabetes medications and is not a substitute for any prescription medication."; "Berberine may affect blood sugar and should not be combined with blood sugar medication without medical supervision."; "This patch won't replace balanced nutrition, movement, or medical care."; "May support normal metabolic function.*"
• Kind Patches, Berberine Patches (GLP-1 Friendly) product page (accessed September 29, 2026): "Berberine Patches (GLP-1 Friendly)"; "High, due to direct absortion" [sic]
• Baptist Health, What Are GLP-1 Patches?, and Cleveland Clinic, What Is a GLP-1 Patch? (accessed September 29, 2026): "Some ingredients act as stimulants and may raise blood pressure or interact with other medications"; "some sellers have rebranded them as berberine patches"; "a condition known as contact dermatitis"

Every source is listed with its address below.

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Compounded medications are not FDA-approved as final products. Product descriptions quoted above are the sellers' own words as published when we read them on September 19 or September 29, 2026, and may change.

Telehealth prescribing rules differ by state. Read the state-by-state guide.